In-vivo Bioequivalence Study of Emtricitabine/Tenofovir 200/25 mg Tablets of The Test Drug (TESCOVI® 200/25 mg Tabs., Sobhan Trade Pharma, Iran)
Not Applicable
- Conditions
- This study is performed on healthy volunteers and drug concentration in plasma is determined..
- Registration Number
- IRCT20200105046010N105
- Lead Sponsor
- Sobhan trading group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
General Health (Liver, Heart, and Kidney)
Body Mass Index 18-28 kg/m^2
Age of 18-55 years old
Informed consent
Exclusion Criteria
Nicotine consumption
history Cardiovascular disease
History Liver and kidney
Alcohol and opioid addiction
Allergy reactions history to Emtricitabine or Tenofovir
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method